ClinicalTrials.gg
TerminatedNCT04093362FOENIX-CCA3Updated Feb 7, 2025Results posted

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

A Phase 3 interventional study of Futibatinib and Cisplatin in Advanced Cholangiocarcinoma and FGFR2 Gene Rearrangements, sponsored by Taiho Oncology, Inc.. Terminated at 103 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Due to Poor Recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Cholangiocarcinoma with a site in Japan — 6 open to participants now, 14 under way, 3 of them phase 3. Cholangiocarcinoma · Japan.

Enrollment
27th of 28
10 · median 163
Started
2021
with 1 other
Phase 3
6 of 31
1 open now
Registered
13th of 31
by date
Lead sponsor
3 of 31
Taiho Oncology, Inc.

Among the 31 studies in Cholangiocarcinoma with a site in Japan, this one is the 27th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2021, is one of 6 in phase 3, and was the 13th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

6 of the 31 studies in Cholangiocarcinoma with a site in Japan are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Cholangiocarcinoma with a site in Japan, or all of them as a file.
02

Study summary

This is an open-label, multinational, parallel 2-arm, randomized Phase 3 study evaluating the efficacy and safety of futibatinib versus gemcitabine-cisplatin chemotherapy as first-line treatment of participants with advanced, metastatic, or recurrent unresectable intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene rearrangements

Read the detailed description

Study TAS-120-301 is an open-label, multinational, parallel 2-arm, randomized Phase 3 study evaluating the efficacy and safety of futibatinib versus gemcitabine-cisplatin chemotherapy as first-line treatment of participants with advanced, metastatic, or recurrent unresectable iCCA harboring FGFR2 gene rearrangements. Eligible participants will be randomized on a 1:1 basis to the following study arms:

  • Experimental Arm: Participants will receive futibatinib at an oral dose of 20 mg, administered daily (QD) on every day of a 21-day cycle.
  • Control Arm: On Days 1 and 8 of a 21-day cycle, participants will receive:

    • Cisplatin 25 mg/m2 in 1000 mL 0.9% saline by intravenous (IV) infusion over 1 hour, followed by 500 millilliteres (mL) 0.9 percent (%) saline over 30 minutes; and
    • Gemcitabine 1000 mg/m2 in 250-500 mL 0.9% saline by IV infusion over 30 minutes, beginning after completion of the cisplatin and saline infusions.

Participants in the Experimental Arm may continue to receive continuous futibatinib until documentation of progressive disease (PD) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1), or until other withdrawal criteria are met, whichever comes first. However, treatment may continue following PD per RECIST 1.1 if the participants is clinically stable and is considered by the Investigator to be deriving continued clinical benefit from futibatinib.

Participants in the Control Arm may receive gemcitabine-cisplatin chemotherapy for up to 8 cycles or until PD or other withdrawal criteria are met, whichever comes first. Participants who discontinue gemcitabine-cisplatin due to documented disease progression (by ICR) may receive treatment with futibatinib ("crossover"), if medically appropriate in the opinion of the Investigator and if criteria for futibatinib treatment are met.

03

Conditions studied

  • Advanced Cholangiocarcinoma
  • FGFR2 Gene Rearrangements

Browse trials for

Keywords

  • Futibatinib
  • Advanced Cholangiocarcinoma
  • FGFR2
  • Fusion
  • Rearrangement
  • TAS-120
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A participant must meet all of the following inclusion criteria to be eligible for enrollment in this study:

  1. Provide written .
  2. Is ≥18 years of age (or meets the country's regulatory definition for legal adult age).
  3. The participant has confirmed, locally advanced, or , or recurrent unresectable iCCA harboring FGFR2 gene rearrangements based on testing performed by the designated central laboratory.
  4. Participant has radiographically per 1.1.
  5. Participants who have received treatment for locally advanced disease (for example, trans-arterial chemoembolization, selective internal radiation therapy, external beam radiation) must have evidence of radiographic progression with measurable disease outside the previously-treated lesions.
  6. performance status (ECOG PS) 0 or 1.
  7. Adequate organ function as defined by the following criteria:

    • (AST) and alanine aminotransferase (ALT) ≤ 3.0 × (ULN); if liver function abnormalities are due to underlying liver metastasis, AST and ALT ≤ 5 × ULN.
    • Total ≤ 1.5 × ULN, or ≤ 3.0 × ULN for participants with Gilbert's syndrome.
    • White Blood Count (WBC) ≥ 2000/mm3 (≥ 2.0 × 109/L)
    • (ANC) ≥ 1000/mm3 (ie, ≥ 1.0 × 109/L by International Units [IU])
    • count ≥ 100,000/mm3 (IU: ≥ 100 × 109/L)
    • ≥ 9.0 g/dL
    • Phosphorus ≤ 1.5 × ULN
    • : ≥ 60 mL/min
  8. Women of (WOCBP) must have a negative serum pregnancy test within 7 days prior to administration of the first dose of futibatinib. Female participants are not considered to be of child bearing potential if they have a history of hysterectomy or are post menopausal defined as no menses for 12 months without an alternative medical cause. Both males and females of must agree to use effective during the study prior to the first dose and for 6 months after the last dose.
  9. Willing and able to comply with scheduled visits and study procedures.

Exclusion criteria

Exclusion Criteria:

A participant will be excluded from this study if any of the following criteria are met:

  1. Participant has received previous systemic anticancer therapy.

    •Participants receiving or neoadjuvant treatment and completed ≥6 months prior to randomization are eligible.

  2. Participant has mixed hepatocellular carcinoma - iCCA disease.
  3. History and/or current evidence of any of the following disorders:

    • Non-tumor related alteration of calcium-phosphorus homeostasis that is in the opinion of the Investigator.
    • Ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, or myocardia and lung, considered clinically significant in the opinion of the Investigator.
    • Retinal disorder confirmed by retinal examination and considered clinically significant in the opinion of the ophthalmologist.
  4. History or current evidence of uncontrolled ventricular arrhythmias
  5. Fridericia's interval (QTcF) > 470 milliseconds (ms) on (ECG) conducted during Screening.
  6. Treatment with any of the following within the specified time frame prior to the first dose of study therapy, or failure to recover from side effects of these prior therapies:

    • Major surgery within the previous 4 weeks (the surgical incision should be fully healed prior to the first dose of study therapy).
    • Radiotherapy (any dose) for extended field within 4 weeks or limited field radiotherapy within 2 weeks, and/or has not recovered from acute impact of radiotherapy.
    • Participants with locoregional therapy, e.g. transarterial chemoembolization (TACE), selective internal radiotherapy (SIRT) or ablation within 4 weeks.
    • Any history of liver transplant.
  7. A serious illness or medical condition(s) including, but not limited to, the following:

    • that are untreated or clinically or radiologically unstable (that is, have been stable for \<1 month).
    • Known acute systemic infection.
    • Myocardial infarction, severe/unstable angina, or symptomatic congestive heart failure within the previous 6 months.
    • Chronic nausea, vomiting, or diarrhea considered to be clinically significant in the opinion of the Investigator.
    • Congenital long QT syndrome, or any known history of torsade de pointes, or family history of unexplained sudden death.
    • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the judgment of the Investigator would make the participant inappropriate for entry into this study.
  8. Participants with a history of another primary that is currently clinically significant, and has potential for or currently requires active intervention.
  9. Pregnant or breast-feeding female.
  10. The participant is unable to take oral medication.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Futibatinib

    Participants received futibatinib at an oral dose of 20 milligrams (mg), administered once daily (QD) on every day of a 21-day cycle up to disease progression.

    Drug: Futibatinib

  • Active comparator
    Cisplatin/Gemcitabine

    Participants received cisplatin 25 milligrams per square meter (mg/m\^2) IV infusion followed by gemcitabine 1000 mg/m\^2 IV infusion on Days 1 and 8 of each 21-day cycle up to 8 cycles.

    Drug: Cisplatin · Drug: Gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time from date of randomization to the date of documentation of disease progression by independent central review (ICR), or date of death, whichever occurs first. Response assessments were made based on Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1, 2009)

    Time frame: Up to approximately 28 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the proportion of participants experiencing a best overall response of partial response (PR) or complete response (CR) as per RECIST 1.1, based on ICR. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters and persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than (\<)10 millimeters (mm) and disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10-mm short axis)

    Time frame: Up to approximately 28 months

  2. Disease Control Rate (DCR)

    DCR was defined as the proportion of participants experiencing a best overall response of stable disease (SD), PR or CR as per RECIST 1.1, based on central assessment of radiologic images. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters and persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm and disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10-mm short axis).

    Time frame: Up to approximately 28 months

  3. Overall Survival (OS)

    OS was defined as the time from the date of randomization until the date of death due to any cause.

    Time frame: Up to approximately 28 months

  4. Progression-Free Survival (PFS) Per Investigator Assessment

    PFS per investigator assessment is defined as the time from date of randomization to the date of disease progression based on investigator assessment of radiographic images or death, whichever occurs first.

    Time frame: Up to approximately 28 months

  5. Number of Participants With Treatment-emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs)

    An adverse event (AE) was defined as any untoward medical condition in clinical investigation participant administered drug; it does not necessarily have to have causal relationship with this treatment. A TEAE was defined as an AE that started or worsened at the time of or after first dose of study drug administration and within 30 days after last dose of study drug and does not necessarily have a causal relationship to use of the study drug. TEAEs were assessed by Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0). SAE was any untoward medical occurrence that at any dose: results in death, is life-threatening, required in participant hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is congenital anomaly/birth defect, important medical event. TEAEs included any clinically significant changes in clinical laboratory tests, vital signs, ophthalmological exams, and 12-lead electrocardiogram (ECG).

    Time frame: Up to approximately 28 months

07

Results

Posted Feb 7, 2025
Limitations and caveats
The data for the outcome measures related to PFS, OS, ORR, DCR, and PFS per Investigator assessment was not collected or analyzed as planned because the study was terminated early due to poor recruitment.

Participant flow

A total of 10 participants took part in the study from 06 January 2021 to 22 April 2024.

Participant flow — Overall Study
MilestoneFutibatinibGemcitabine-Cisplatin
Started46
Completed00
Not completed46
Withdrew: Study termination11
Withdrew: Withdrawal of consent10
Withdrew: Death13
Withdrew: Reason not specified12

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS was defined as the time from date of randomization to the date of documentation of disease progression by independent central review (ICR), or date of death, whichever occurs first. Response assessments were made based on Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1, 2009)

Time frame:
Up to approximately 28 months

No measurements were reported for this outcome.

SecondaryObjective Response Rate (ORR)

ORR was defined as the proportion of participants experiencing a best overall response of partial response (PR) or complete response (CR) as per RECIST 1.1, based on ICR. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters and persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than (\<)10 millimeters (mm) and disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10-mm short axis)

Time frame:
Up to approximately 28 months

No measurements were reported for this outcome.

SecondaryDisease Control Rate (DCR)

DCR was defined as the proportion of participants experiencing a best overall response of stable disease (SD), PR or CR as per RECIST 1.1, based on central assessment of radiologic images. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters and persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm and disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10-mm short axis).

Time frame:
Up to approximately 28 months

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization until the date of death due to any cause.

Time frame:
Up to approximately 28 months

No measurements were reported for this outcome.

SecondaryProgression-Free Survival (PFS) Per Investigator Assessment

PFS per investigator assessment is defined as the time from date of randomization to the date of disease progression based on investigator assessment of radiographic images or death, whichever occurs first.

Time frame:
Up to approximately 28 months

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs)

An adverse event (AE) was defined as any untoward medical condition in clinical investigation participant administered drug; it does not necessarily have to have causal relationship with this treatment. A TEAE was defined as an AE that started or worsened at the time of or after first dose of study drug administration and within 30 days after last dose of study drug and does not necessarily have a causal relationship to use of the study drug. TEAEs were assessed by Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0). SAE was any untoward medical occurrence that at any dose: results in death, is life-threatening, required in participant hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is congenital anomaly/birth defect, important medical event. TEAEs included any clinically significant changes in clinical laboratory tests, vital signs, ophthalmological exams, and 12-lead electrocardiogram (ECG).

Time frame:
Up to approximately 28 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs)
ParticipantsFutibatinibGemcitabine-Cisplatin
TEAEs45
SAEs23

Adverse events

Collected over From first dose of study drug up to end of study (Up to approximately 28 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Futibatinib1/4 (25%)2/4 (50%)4/4 (100%)
Gemcitabine-Cisplatin3/5 (60%)3/5 (60%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventFutibatinibGemcitabine-Cisplatin
Abdominal sepsisInfections and infestations0/42/5
Abdominal painGastrointestinal disorders1/40/5
Oesophageal varices haemorrhageGastrointestinal disorders1/40/5
DyspnoeaRespiratory, thoracic and mediastinal disorders1/40/5
ThrombocytopeniaBlood and lymphatic system disorders0/41/5
General physical health deteriorationGeneral disorders0/41/5
HyponatraemiaMetabolism and nutrition disorders0/41/5
Acute kidney injuryRenal and urinary disorders0/41/5
Most frequent other events
Showing 10 of 71
Most frequent other events
EventFutibatinibGemcitabine-Cisplatin
NauseaGastrointestinal disorders0/45/5
HyperphosphataemiaMetabolism and nutrition disorders3/40/5
Abdominal painGastrointestinal disorders1/43/5
ConstipationGastrointestinal disorders0/43/5
Oedema peripheralGeneral disorders0/43/5
AnaemiaBlood and lymphatic system disorders0/43/5
DiarrhoeaGastrointestinal disorders2/42/5
AlopeciaSkin and subcutaneous tissue disorders2/40/5
PruritusSkin and subcutaneous tissue disorders2/40/5
AscitesGastrointestinal disorders1/42/5

Baseline characteristics

All Randomized Population included participants randomized to any treatment group in the study.

Age, Continuous
Age, Continuous(years)FutibatinibGemcitabine-CisplatinTotal
Mean69.3 ± 9.4656.3 ± 12.7761.5 ± 12.84
Sex: Female, Male
Sex: Female, Male(Participants)FutibatinibGemcitabine-CisplatinTotal
Female145
Male325
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FutibatinibGemcitabine-CisplatinTotal
Hispanic or Latino134
Not Hispanic or Latino325
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FutibatinibGemcitabine-CisplatinTotal
American Indian or Alaska Native000
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American000
White257
More than one race000
Unknown or Not Reported011
08

Study locations

103 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Norton Cancer Institute Audubon Hospital Campus Medical Plaza
    Louisville, Kentucky 40217, United States
  • New Mexico Cancer Care Alliance
    Albuquerque, New Mexico 87131, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
  • University of Virginia Cancer Center
    Charlottesville, Virginia 22908, United States
  • Medical Oncology Associates, PS - Summit Cancer Centers
    Spokane, Washington 99208, United States
  • Carbone Comprehensive Cancer Center
    Madison, Wisconsin 53792, United States
  • Medical College of Wisconsin - Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • Fundacion Favaloro para la Docencia e Investigacion Medica
    Buenos Aires, Caba C1093, Argentina
  • Hospital de Gastroenterologia Dr. C. Bonorino Udaondo
    Buenos Aires, Caba CP1264, Argentina
  • Newcastle Private Hospital
    Newcastle, New South Wales 2305, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3002, Australia
  • UZ Antwerpen
    Edegem, Antwerpen 2650, Belgium
  • Algemeen Ziekenhuis AZ Sint-Maarten
    Mechelen, Antwerpen 2800, Belgium
  • AZ Delta Roeselare
    Roeselare, Flemish Region 8800, Belgium
  • CHC MontLégia
    Liège, Liege 4000, Belgium
  • IOP - Instituto de Oncologia do Parana
    Curitiba, PR 80520-174, Brazil
  • Instituto Nacional de Cancer Jose Alencar Gomes da Silva - INCA
    Rio De Janeiro, RJ 20231-050, Brazil
  • Instituto Americas
    Rio De Janeiro, RJ 22775-001, Brazil
  • Cepho-Fm Abc
    Santo Andre, SP 09060-650, Brazil
  • Hospital de Base de Sao Jose do Rio Preto
    São José Do Rio Preto, SP 15090-000, Brazil
  • Instituto do Cancer do Estado de Sao Paulo
    São Paulo, SP 01246-000, Brazil
  • Fundacao Antonio Prudente - A.C.Camargo Cancer Center
    São Paulo, SP 01509-010, Brazil
  • Hospital Municipal Vila Santa Catarina
    São Paulo, SP 04377-035, Brazil
  • Hospital Santa Marcelina HSM
    São Paulo, SP 08270-120, Brazil
  • Hopitaux Universitaires Paris Nord Val de Seine - Hopital Beaujon
    Clichy, 92110, France
  • Centre Georges-Francois Leclerc
    Dijon, 21000, France
  • Centre Hospitalier Universitaire de Grenoble
    La Tronche, 38700, France
  • Centre Leon Berard
    Lyon, 69008, France
  • CHRU Besancon
    Montbéliard, 25 200, France
  • CHU Reims
    Reims, 51092, France
  • Institut de Cancerologie Strasbourg Europe ICAENS
    Strasbourg, 67033, France
  • CHU de TOURS - Hopital Trousseau
    Tours, 37044, France
  • Charite - Universitaetsmedizin Berlin
    Berlin, 13353, Germany
  • Universitaetsmedizin Mainz
    Mainz, 55131, Germany
  • Technische Universitaet Muenchen - Klinikum rechts der Isar
    Muenchen, Muenchen, Germany
  • The University of Hong Kong, Queen Mary Hospital
    Hong Kong, 2255-4249, Hong Kong
  • The Chinese University of Hong Kong Prince of Wales Hospital
    Shatin, Hong Kong
  • Candiolo Cancer Institute - FPO IRCCS
    Candiolo, Italy
  • Ospedale Versilia
    Lucca, 555041, Italy
  • AOU di Cagliari
    Monserrato, 9042, Italy
  • Ospedale Maggiore della Carita di Novara
    Novara, 28100, Italy
  • Servizio Sanitario Regionale Emilia-Romagna - Azienda Ospedaliero-Universitaria di Parma Ospedale Maggiore
    Parma, 43126, Italy
  • Policlinico Uni. Campus Bio-Medico
    Roma, 12800, Italy
  • Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte
    Siena, 53100, Italy
  • AOUI Verona - Ospedale Borgo Roma
    Verona, 37134, Italy
  • Azienda ULSS 8 Berica
    Vicenza, 36100, Italy
  • Nagoya University Hospital
    Nagoya, Aichi 466-8560, Japan
  • Chiba University Hospital
    Chiba-shi, Chiba 260-8677, Japan
  • National Cancer Center Hospital East
    Kashiwa-Shi, Chiba 277-8577, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka-shi, Fukuoka 811-1395, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • Kanagawa Cancer Center
    Yokohama-Shi, Kanagawa 241-8515, Japan
  • Nagasaki University Hospital
    Nagasaki-shi, Nagasaki 852-8501, Japan
  • Osaka city University Hospital
    Osaka-shi, Osaka 545-8586, Japan
  • Osaka University Hospital
    Suita-shi, Osaka 565-0871, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
  • The Cancer Institute Hospital of JFCR
    Koto-Ku, Tokyo 135-8550, Japan
  • Kyorin University Hospital
    Mitaka-shi, Tokyo 181-8611, Japan
  • Chonnam National University Hwasun Hospital
    Hwasun, Jeollanam-Do 58128, Korea, Republic of
  • Seoul National University Hospital
    Jungni I Gu, Seoul 3080, Korea, Republic of
  • Asan Medical Center
    Seul, Seoul 5505, Korea, Republic of
  • Dong-A University Hospital
    Busan, 49201, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, 41944, Korea, Republic of
  • CHA Bundang Medical Center
    Seongnam, 13496, Korea, Republic of
  • Yonsei University Health System - Severance Hospital
    Seoul, 3722, Korea, Republic of
  • Samsung Medical Center
    Seoul, 6351, Korea, Republic of
  • Centro de Estudios y Prevencion del Cancer (CEPREC)
    Tuxtla Gutiérrez, Chiapas 29038, Mexico
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    Mexico City, MX 14080, Mexico
  • Hospital Universitario Jose Eleuterio Gonzalez
    Monterrey, Nuevo Leon 64460, Mexico
  • Radboud University Medical Center
    Nijmegen, GA 6525, Netherlands
  • Hospital Daniel Alcides Carrion
    Bellavista, Callao 07016, Peru
  • Instituto Nacional de Enfermedades Neoplasicas (INEN)
    Surquillo, Lima 15038, Peru
  • Hospital Goyeneche
    Arequipa, 04001, Peru
  • Hospital Nacional Arzobispo Loayza
    Lima, 15082, Peru
  • Centrum Medyczne HCP Sp. z o.o.
    Poznań, Wielkopolskie 61-485, Poland
  • Szpital Kliniczny Przemienienia Pańskiego UM im. Karola Marcinkowskiego w Poznaniu
    Poznań, Woj. Wielkopolskie 60-569, Poland
  • Fundacao Champalimaud
    Lisboa, 1400-038, Portugal
  • CUF Porto Hospital
    Porto, 4100-180, Portugal
  • Instituto Portugues de Oncologia do Porto
    Porto, 4200-072, Portugal
  • Onkologikoa
    Donostia-San Sebastian, Gipuzkoa 20014, Spain
  • Hospital Universitario Virgen de la Arrixaca HUVA
    El Palmar, Murcia 30120, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Clinica Universidad de Navarra
    Madrid, 28022, Spain
  • MD Anderson Cancer Center
    Madrid, 28033, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28043, Spain
  • Clinica Universidad de Navarra
    Pamplona, Spain
  • Chang Gung Memorial Hospital CGMH - Kaohsiung Branch
    Kaohsiung, 83301, Taiwan
  • Chang Gung Memorial Hospital, Linkou
    Taichung, 40447, Taiwan
  • National Cheng Kung University Hospital NCKUH
    Tainan, 704, Taiwan
  • Chi Mei Medical Center CMMC - Yongkang branch
    Tainan, 710, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Khon Kaen University KKU - Faculty of Medicine-Srinagarind Hospital
    Khon Kaen, Muang 40002, Thailand
  • Songklanagarind Hospital, Faculty of Medicine, Prince of Songkla University
    Hat Yai, Songkhla 90110, Thailand
  • Chulabhorn Hospital, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy
    Bangkok, 10210, Thailand
  • Rajavithi hospital
    Bangkok, 10400, Thailand
  • Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University
    ChiangMai, 50200, Thailand

Showing the first 100 of 103 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Apr 2024, 39 months.

Results were first posted in Feb 2025, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2019
First posted
Sep 18, 2019
StartActual
Jan 6, 2021
Primary completionActual
Apr 22, 2024
CompletionActual
Apr 22, 2024
Results first posted
Feb 7, 2025
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04093362
Responsible party
Sponsor
First posted
Sep 18, 2019
Start date
Jan 6, 2021
Primary completion
Apr 22, 2024
Completion
Apr 22, 2024
Results posted
Feb 7, 2025
Last update
Feb 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Futibatinib

Start the discussion